Miglustat Gen.Orph 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued2 / 
affected3  
amended 
on 
IB/0024 
C.I.2.a - Change in the SPC, Labelling or PL of a 
13/03/2023 
SmPC and PL 
To update section 4.4, 4.6 and 5.3 in order to improve 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
clarity following assessment of same changes for reference 
product. Package leaflet has been updated accordingly. 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
II/0023 
Please refer to the Recommendations section. 
09/02/2023 
n/a 
Not applicable 
B.I.a.1.z - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - Other 
variation 
R/0022 
Renewal of the marketing authorisation. 
21/07/2022 
19/09/2022 
SmPC, Annex 
Based on the review of data on quality, safety and efficacy, 
II, Labelling 
the CHMP considered that the benefit-risk balance of 
and PL 
Miglustat Gen.Orph in the approved indication remains 
favourable and therefore recommended the renewal of the 
marketing authorisation with unlimited validity. 
IB/0021 
B.II.e.1.b.1 - Change in immediate packaging of the 
11/01/2022 
19/09/2022 
SmPC, 
finished product - Change in type/addition of a new 
container - Solid, semi-solid and non-sterile liquid 
pharmaceutical forms 
Labelling and 
PL 
IAIN/0020/G 
This was an application for a group of variations. 
01/12/2021 
19/09/2022 
Annex II and 
PL 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.5.b - Change to in-process tests or limits 
applied during the manufacture of the finished 
product - Addition of a new test(s) and limits 
B.II.b.2.c.2 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Including batch control/testing 
B.II.b.1.b - Replacement or addition of a 
manufacturing site for the FP - Primary packaging 
site 
Page 2/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
II/0018 
B.I.z - Quality change - Active substance - Other 
02/09/2021 
n/a 
variation 
IB/0017/G 
This was an application for a group of variations. 
27/08/2021 
n/a 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
B.I.b.z - Change in control of the AS - Other 
variation 
IB/0019 
B.II.b.3.z - Change in the manufacturing process of 
12/08/2021 
n/a 
the finished or intermediate product - Other variation 
IB/0016 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
28/01/2021 
n/a 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
IA/0015/G 
This was an application for a group of variations. 
18/12/2020 
n/a 
B.III.1.b.3 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
Updated certificate from an already approved 
manufacturer 
B.III.1.b.3 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
Updated certificate from an already approved 
manufacturer 
Page 3/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.III.1.b.3 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
Updated certificate from an already approved 
manufacturer 
B.III.1.b.2 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
New certificate for a starting 
material/reagent/intermediate/or excipient from a 
new or an already approved manufacturer 
II/0013 
B.I.z - Quality change - Active substance - Other 
29/10/2020 
n/a 
variation 
IB/0014/G 
This was an application for a group of variations. 
07/10/2020 
n/a 
B.II.b.5.z - Change to in-process tests or limits 
applied during the manufacture of the finished 
product - Other variation 
B.II.b.5.z - Change to in-process tests or limits 
applied during the manufacture of the finished 
product - Other variation 
IA/0012/G 
This was an application for a group of variations. 
29/07/2020 
n/a 
B.I.a.1.f - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - 
Changes to quality control testing arrangements for 
the AS -replacement or addition of a site where 
batch control/testing takes place 
B.I.a.3.a - Change in batch size (including batch size 
ranges) of AS or intermediate - Up to 10-fold 
Page 4/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
increase compared to the originally approved batch 
size 
N/0011 
Minor change in labelling or package leaflet not 
28/05/2020 
19/09/2022 
PL 
connected with the SPC (Art. 61.3 Notification) 
IB/0010/G 
This was an application for a group of variations. 
08/04/2020 
n/a 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
N/0009 
Minor change in labelling or package leaflet not 
03/03/2020 
28/04/2020 
PL 
connected with the SPC (Art. 61.3 Notification) 
IA/0008 
B.II.b.3.a - Change in the manufacturing process of 
12/12/2019 
n/a 
the finished or intermediate product - Minor change 
in the manufacturing process 
IA/0007 
B.II.b.4.a - Change in the batch size (including batch 
02/10/2019 
n/a 
size ranges) of the finished product - Up to 10-fold 
compared to the originally approved batch size 
II/0003 
B.I.a.1.b - Change in the manufacturer of AS or of a 
04/07/2019 
n/a 
Page 5/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
starting material/reagent/intermediate for AS - 
Introduction of a manufacturer of the AS supported 
by an ASMF 
IB/0006 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
22/05/2019 
28/04/2020 
SmPC 
life of the finished product - As packaged for sale 
(supported by real time data) 
IB/0005 
C.I.2.a - Change in the SPC, Labelling or PL of a 
26/03/2019 
29/04/2019 
SmPC, 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
Labelling and 
PL 
N/0002 
Minor change in labelling or package leaflet not 
02/05/2018 
25/02/2019 
Labelling and 
connected with the SPC (Art. 61.3 Notification) 
PL 
IAIN/0001 
A.1 - Administrative change - Change in the name 
02/03/2018 
25/02/2019 
SmPC, 
and/or address of the MAH 
Labelling and 
PL 
Page 6/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
